News


Life Science | 2019-10-29
Kuros convenes Extraordinary General Meeting

Schlieren (Zurich), Switzerland, October 29, 2019 – Kuros Biosciences (SIX: KURN) today announced that it will hold an Extraordinary General Meeting (EGM) of shareholders to seek approval to increase the Company’s ordinary share capital. The EGM will be held at Kuros Biosciences AG, Wagistrasse 25, 8952 Schlieren, Switzerland on 19 November 2019 at 10.00am CET.

The share capital increase aims at raising approximately CHF 6 to 12 million. The Company intends to use the net proceeds of the Offering primarily to accelerate and advance the commercial roll-out of MagnetOs, based on its early performance and growth potential. Recently, at NASS, the leading spinal surgery meeting, data were presented demonstrating that MagnetOs significantly outperformed comparator products in achieving uniform, solid and stable spinal fusions. Kuros is also considering additional investment in the clinical development of Fibrin-PTH, which targets a substantial clinical need and potentially a significant commercial opportunity, to strengthen its strategic position after the Phase 2a study results become available in the first half of 2021.

The EGM invitation can be downloaded via the following links:

http://www.kuros.ch/uploads/Corporate_Governance/Kuros_EGM_Invitation_Nov2019.pdf

http://www.kuros.ch/uploads/Corporate_Governance/Kuros_EGV_Einladung_Nov2019.pdf

For further information, please contact:

Kuros Biosciences AG                             Media & Investors

Michael Grau                                        Hans Herklots

Chief Financial Officer                            LifeSci Advisors

Tel +41 44 733 47 47                            +41 79 598 71 49

michael.grau@kurosbio.com                   hherklots@lifesciadvisors.com

 

About Kuros Biosciences AG

Kuros Biosciences is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland, Bilthoven, The Netherlands and Burlington, MA, U.S. The Company is listed according to the International Financial Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit www.kurosbio.comfor additional information on Kuros, its science and product pipeline.

 

About MagnetOs

MagnetOs bone graft has an advanced submicron surface topography that leads to the formation of bone, rather than scar tissue, following implantation. In preclinical models, MagnetOs preferentially directs early wound healing toward the bone-forming pathway, meaning that bone can be formed even in soft tissues without the need for added cells or growth factors, resulting in an osteoinductive claim in Europe. MagnetOs promotes local bone formation equivalent to current gold standard, autograft. A substantial number of clinically relevant and predictive studies have demonstrated its equivalence to the current gold standard (patient’s own bone, which may not be available in sufficient quantities and/or involves morbidity, costs and pain associated with its harvesting from another healthy site of the patient’s body). MagnetOs is now supported by over two years’ clinical experience since its launch in the United Kingdom in May 2017. For more information, see: www.magnetosbonegraft.com.

 

About Fibrin-PTH (KUR-113)

Fibrin-PTH (KUR-113) consists of a natural fibrin-based healing matrix with an immobilized targeted bone growth factor (truncated human parathyroid hormone (PTH) analog). Fibrin-PTH (KUR-113) is designed to be applied directly into and around an intervertebral body fusion device as a gel, where it polymerizes in situ. Fibrin-PTH (KUR-113) functions via the well-established mechanism of action of parathyroid hormone; has been demonstrated in animal models of spinal fusion to be comparable to rhBMP-2; and has been shown in preclinical studies to be easy to use and ideal for open or minimally invasive techniques. Fibrin PTH (KUR-113) is an investigational drug/biologic combination product candidate. Fibrin PTH (KUR-113) has been evaluated in animals for use in lumbar interbody fusion. The safety & efficacy of Fibrin PTH (KUR-113) has not yet been evaluated for spinal fusion in humans.

 

Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.


Last News

2019-10-29
Kuros convenes Extraordinary General Meeting
 
Legal informationrealisation digitalcube